Renaissance Capital logo

Stoke Therapeutics Priced, Nasdaq: STOK

Preclinical biotech developing RNA-targeted therapies for rare genetic diseases.

Industry: Health Care

Latest Trade: $31.82 0.00 (0.0%)

First Day Return: +42.1%

Return from IPO: +76.8%

Industry: Health Care

We are pioneering a new way to treat the underlying causes of severe genetic diseases by precisely upregulating protein expression. We are developing novel antisense oligonucleotide, or ASO, medicines that target ribonucleic acid, or RNA, and modulate precursor-messenger RNA, or pre-mRNA, splicing to upregulate protein expression where needed and with appropriate specificity to near normal levels. We utilize our proprietary technology platform, Targeted Augmentation of Nuclear Gene Output, or TANGO, to design ASOs to upregulate the expression of protein by individual genes in a patient. Our approach is designed to allow us to deliver in a highly precise, durable and controlled manner disease-modifying therapies to a wide range of relevant tissues, including the central nervous system, or CNS, eye, kidney and liver. We designed our lead product candidate, STK-001, to treat Dravet syndrome, a severe and progressive genetic epilepsy. With a well-defined patient population based on routine genetic testing and learnings from recently approved drugs for the treatment of Dravet syndrome to inform the clinical and regulatory pathways, we anticipate an efficient clinical program for STK-001. We plan to submit an investigational new drug application for STK-001 by early 2020 and expect to initiate a Phase 1/2 clinical trial in the first half of 2020. We intend to nominate a second candidate to treat an additional genetic disease for preclinical development by the first half of 2020.
more less
IPO News for Stoke Therapeutics
more
IPO Data
IPO File Date 05/23/2019
Offer Price $18.00
Price Range $14.00 - $16.00
Offer Shares (mm) 7.9
Deal Size ($mm) $142
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 06/18/2019
Offer Price $18.00
Price Range $14.00 - $16.00
Offer Shares (mm) 7.9
Deal Size ($mm) $142
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters Bedford, MA
Founded 2014
Employees 44
Website www.stoketherapeutics.com